Roflumilast Foam 0.3%
ARQ-154-203
Phase 2 small_molecule completed
Quick answer
Roflumilast Foam 0.3% for Seborrheic Dermatitis is a Phase 2 program (small_molecule) at Arcutis Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Arcutis Biotherapeutics
- Indication
- Seborrheic Dermatitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed